论文部分内容阅读
目的:系统评价奥扎格雷钠联合灯盏细辛制剂治疗脑梗死的疗效和安全性。方法:计算机检索Pub Med,EMbase,Cochrane Library,西文生物医学期刊文献数据库,中国期刊全文数据库,维普数据库,万方数据库,收集奥扎格雷钠联合灯盏细辛制剂治疗脑梗死的临床随机对照实验(RCT)。对纳入的研究进行方法学质量评价,并采用Rev Man 5.3.4统计软件进行Meta分析。结果:共纳入22项RCT,合计2 198例患者。Meta分析结果显示,奥扎格雷钠联合灯盏细辛制剂能够显著提高患者的总有效率[OR=3.76,95%CI(2.84,4.97),P<0.000 01]、显效率[OR=2.07,95%CI(1.71,2.49),P<0.000 01]及改善神经功能缺损评分[MD=-5.08,95%CI(-5.73,-3.53),P<0.000 01],差异均有统计学意义。结论:奥扎格雷钠联合灯盏细心制剂治疗脑梗死疗效显著,未见明显不良反应,但受纳入文献质量限制,其疗效有待于高质量的随机对照实验进一步证实。
OBJECTIVE: To systematically evaluate the efficacy and safety of ozagrel combined with erigeron in the treatment of cerebral infarction. METHODS: Randomized controlled clinical trials of Ozagrel combined with Erigeron Breviscapus for the treatment of cerebral infarction were collected from PubMed, EMbase, Cochrane Library, Western Chinese Medical Periodical Literature Database, Chinese Journal Full-text Database, VIP database and Wanfang database (RCT). The included studies were evaluated for methodological quality and Meta-analysis was performed using Rev Man 5.3.4 statistical software. Results: A total of 22 RCTs were included, totaling 2 198 patients. Meta-analysis showed that sodium ozagrel combined with erigeron can significantly improve the total effective rate [OR = 3.76,95% CI (2.84,4.97, P <0.000 01], significant efficiency [OR = 2.07,95 % CI (1.71,2.49), P <0.000 01] and improvement of neurological deficit scores [MD = -5.08,95% CI (-5.73, -3.53), P <0.000 01]. The differences were statistically significant. CONCLUSION: Ozagrel sodium combined with Dengzhu attentive preparation has a significant curative effect on cerebral infarction. No obvious adverse reactions have been reported. However, the quality of the literature is limited, and its curative effect needs to be further confirmed by high-quality randomized controlled trials.